Rg3 is extracted from traditional Chinese medicine, red ginseng. However, due to its poor aqueous solubility and low oral bioavailability, the use of 20(s)-Rg3 is limited. This study aimed to explore a method of preparing nano-sized 20(s)-ginsenoside Rg3 particle named 20(s)-ginsenoside Rg3-loaded magnetic human serum albumin nanospheres (20(s)-Rg3/HSAMNP) to change dosage form to improve its aqueous solubility and bioavailability. 20(s)-Rg3/HSAMNP were prepared by the desolvation-crosslinking method. The character of 20(s)-Rg3/HSAMNP was detected. An antiproliferative effect and cell apoptosis rates of 20(s)-Rg3/HSAMNP on human cervical cancer cells were determined by the MTT assay and flow cytometry, respectively. TEM analysis showed that 20(s)-Rg3/HSAMNP were approximately spherical and uniform in size. Thermodynamic testing showed that the corresponding magnetic fluid of a specific concentration rosed to a steady temperature of 42-65°C. Iron content was approximately 3 mg/mL. Drug encapsulation efficiency was approximately 70%. The potential of 20(s)-Rg3/HSAMNP combined with magnetic hyperthermia therapy to inhibit cell growth and induce apoptosis was much more prominent than that of the other groups. A new dosage form of 20(s)-Rg3 was prepared, which effectively induced apoptosis in HeLa cervical cancer cells in vitro when combined with hyperthermia.
Introduction
Ginseng is a valuable traditional Chinese medicine and famous for its effect on enriching consumptive disease. Bioactive compounds in ginseng possess a series of beneficial effects in the prevention of cancer [1], diabetes [2] and cardiovascular disease [3] . 20(s)-ginsenoside Rg3 (20(s)-Rg3) is extracted from red ginseng with a molecular formula of C 42 H 72 O 13 and can suppress tumor cell proliferation and induces tumor cell apoptosis [4] . However, due to its poor aqueous solubility and low oral bioavailability, the use of 20(s)-Rg3 is limited. A safer and more efficient agent is needed to improve 20(s)-Rg3 bioavailability. Biocompatible and biodegradable albumin microspheres are made with human or animal albumin and have the size of a micron grade ball. They have the advantage of being non-toxic and nonimmunogenic [5] . Human serum albumin (HAS) is a versatile drug carrier because of its small size and abundance in blood plasma. The accumulation in malignant and inflamed tissue of HSA agents can confer good biodistribution and deliver a significantly increased dose in tumors.
Magnetic fluid hyperthermia(MFH) involves injecting a nanoscale magnetic liquid into the target area of the tumor to attain a temperature effective for killing cancer cells upon exposure to an alternating magnetic field, resulting in a therapeutic temperature around the tumor but without damage to normal tissue. Tumor cells have a stronger ability to absorb nanoscale magnetic nanoparticles and a higher sensitivity to hyperthermia, which also provides broad prospects for tumor hyperthermia [6, 7] . Fe 3 O 4 has tremendous properties of magnetism, catalysis, and wave absorption, which makes it the most commonly used magnetic fluid for tumor hyperthermia [8] . However, Fe 3 O 4 has a short half-life and no specific tumor-targeting effects, because it is easily taken up by reticuloendothelial cells and removed by macrophages. Consequently, it is important to identify a good carrier to overcome these disadvantages.
In this study, HAS nanospheres was firstly designed to encapsulate Chinese herbs extracts, 20(s)-Rg3 to improve its solubility and bioavailability. Then Fe 3 O 4 was contained into to improve the therapeutic efficacy by combining chemotherapy with Hyperthermia.
Materials and methods

Materials
HeLa cells were obtained from Shanghai Institute of Cell Biology (Shanghai, China) and cultured in RPMI 1640 medium (folic acid-free, FA-free) (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Shanghai Institute), 100 U/mL penicillin, and 100 mg/mL streptomycin. The cells were maintained at 37°C in a humidified incubator with 5% CO 2 .
HSA and 20(s)-Rg3 were purchased from Pureone Biotechnology (Shanghai, China). The Annexin V-FITC Apoptosis Detection Kit was supplied by Beyotime Institute of Biotechnology (Shanghai, China). Fe 3 O 4 was prepared as described by Li [9] . All reagents were of analytical grade.
Synthesis of 20(s)-Rg3/HSAMNP
20(s)-Rg3/HSAMNP were prepared by a desolvation-crosslinking technique [10] . Briefly, HSA (250 mg), Fe 3 O 4 (50 mg), and 20(s)-Rg3 (5mg) were dissolved in deionized water (25 mL). The pH was adjusted to 8.0 after mixing. Absolute alcohol (150 mL) was added to the solution and stirred at room temperature until a precipitate appeared. Subsequently, 2.5% glutaraldehyde (50 ȝL) solution was added to the solution and stirred for 12 h. Finally, the mixture was centrifuged at 1500 rpm for 10 min to remove unencapsulated Fe 3 O 4 and at 21,000 rpm for 30 min to remove unencapsulated 20(s)-Rg3. Magnetic human serum albumin nanospheres(HSAMNP) and 20(s)-Rg3 human serum albumin nanospheres ( 20(s)-Rg3/HSANP) were prepared using the same method.
Characterization of 20(s)-Rg3/HSAMNP
Morphology assessed by TEM
The morphology of 20(s)-Rg3/HSAMNP was assessed by TEM.
Dynamic light-scattering analysis
The particle size and size distribution of the 20(s)-Rg3/HSAMNP were assessed by dynamic lightscattering analysis (DLS; Brookhaven Instruments Co., Holtsville, NY, USA).
Iron content and thermodynamic test
Iron content was measured using 1,10-phenanthroline spectrophotometry as described by Wu [11] . The sample in the tube was placed on SPG-06A high-frequency induction heating equipment (Shenzhen, China) (f = 200 kHz, I = 20 A) for 60 min for the thermodynamic test with different iron concentrations. The distance between the bottom of the tube and the center of the alternating magnetic field (AMF) heating coil was 0.5 cm. The temperature was tested using a digital thermometer every 5 minutes.
Drug encapsulation, loading, and drug release
Vanillin-sulfuric acid spectrophotometry was used to detect 20(s)-Rg 3 content. A 1-mL aliquot of 20(s)-Rg3/HSAMNP was dispersed into 9 mL 0.5% pepsin aqueous solution and digested for 3 h at 37°C. After centrifuging for 30 min at 21,000 rpm, the sediment was added into 5% vanillin-acetic acid and perchloric acid and dissolved in an 80°C water bath for 10 min. Finally, 4.0 ml glacial acetic acid was added after allowing the solution to stand for 15 min. The solution was analysed by using UV spectrophotometry (DU 800, Beckman Coulter, Brea, CA, USA) for the drug content at 588 nm. The absorbance of the diluted sample obtained from the 20(s)-Rg3 standard solution was used for standard curve preparation. Drug encapsulation efficiency (DEE) was calculated by the formula: DEE (%) = actual amount of drug encapsulated in MNP/initial amount of drug used in the fabrication of MNP×100%. Drug loading efficiency was calculated by the formula: Drug loading efficiency (%) = actual amount of drug encapsulated in MNP/actual amount of MNP×100%.
Free 20(s)-Rg 3 and 20(s)-Rg 3 nanoparticle release characteristics were tested in vitro. A 20(s)-Rg 3 solution (15 mL) and sample (15 mL) were placed in a dialysis bag, which was immersed in a 50-mL centrifuge tube containing 30 mL PBS (pH 6.0). The tube was placed in a shaking incubator at 37°C and 110 rpm. A 5-mL sample was removed from the centrifuge tube and replaced with 5 mL fresh PBS at regular time intervals. The 20(s)-Rg 3 concentration in each sample was quantified using a standard curve, and the cumulative release rate Q (%) was calculated by Eq. (1):
(1) where and are the drug concentration in released mediators, is the volume of mediator removed, is the total amount of leaching mediator, and and are the weight of the microspheres and drug concentration in the microspheres, respectively. 
MTT assay
Statistical analysis
Values were shown as means ± standard deviation (SD). The data were analyzed with the SPSS 16.0 program. A p value of <0.05 was considered significant.
Results and discussion
Characterization of 20(s)-Rg3/HSAMNP
The TEM sample (Figure 1 ) was round and uniform in size. 20(s)-Rg3/HSAMNP had a magnetic core and led to no aggregation with each other. The nanoparticle size and size distribution measured by DLS are shown in Figure 2 . The diameter of 20(s)-Rg3/HSAMNP was 179.8±1.2 nm, which is a size that can be easily taken up by tumor cells. 20(s)-Rg3 is given priority in preparing oral medications because of its poor solubility in water. The structure of it was shown in Figure 3 . It is easily metabolized by intestinal flora and enzymes, coupled with the first-pass effect, which lead to low plasma concentrations. However, it showed good water solubility when coated with HSA. HSA had stable performance, no toxic side effects, no immunogenicity, and good biocompatibility, which make it an ideal drug carrier, particularly for antitumor drugs.
The iron content of 20(s)-Rg3/HSAMNP was 3 mg/mL. When placed on SPG-06A, 20(s)-Rg3/HSAMNP showed good heating ability, which was stabilized after 35 minutes (Figure 4 ). The iron concentration was correlated with temperature: the greater the iron concentration, the stronger the heating and the higher the rise in temperature.
The regression equation of the drug was , . A and C are the A values and the 20(s)-Rg3 concentration, respectively. It was confirmed that the DEE was approximately 70%, and drug loading efficiency was approximately 1.3%. The free 20(s)-Rg 3 and 20(s)-Rg 3HSAMNP release characteristics were displayed in Figure 5 
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